You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Pralsetinib

Showing 1 - 8 of 8
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Medullary Thyroid Cancer Trial in Cordoba, Sevilla (Pralsetinib, Cabozantinib, Vandetanib)

Not yet recruiting
  • Medullary Thyroid Cancer
  • Pralsetinib
  • +2 more
  • Cordoba, Spain
  • +1 more
Jan 11, 2023

NSCLC, Medullary Thyroid Cancer Trial (pralsetinib (BLU-667))

Approved for marketing
  • Non-Small Cell Lung Cancer
  • Medullary Thyroid Cancer
  • pralsetinib (BLU-667)
  • (no location specified)
Aug 9, 2021

Pralsetinib to Best Available Therapy in RET-Fusion Positive

Enrolling by invitation
  • RET-fusion Non Small Cell Lung Cancer
  • +16 more
    • New York, New York
    • +2 more
    Aug 9, 2021

    NSCLC Trial in Worldwide (Alectinib, Entrectinib, Pralsetinib)

    Recruiting
    • Non-Small Cell Lung Cancer
    • San José, Costa Rica
    • +3 more
    Aug 4, 2022

    RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide

    Active, not recruiting
    • RET-altered Non Small Cell Lung Cancer
    • +39 more
    • pralsetinib (BLU-667)
    • Phoenix, Arizona
    • +65 more
    Nov 10, 2022

    NSCLC Trial in United States (Alectinib, Entrectinib, Vemurafenib)

    Recruiting
    • Non-small Cell Lung Cancer
    • Duarte, California
    • +24 more
    Feb 2, 2023

    Advanced Unresectable or Metastatic Solid Malignancy Trial in United States (Entrectinib, Inavolisib, Alectinib)

    Recruiting
    • Advanced Unresectable or Metastatic Solid Malignancy
    • Birmingham, Alabama
    • +50 more
    Aug 10, 2022

    Solid Tumors Trial in Worldwide (Entrectinib, Alectinib, Atezolizumab)

    Recruiting
    • Solid Tumors
    • Daphne, Alabama
    • +156 more
    Jan 13, 2023